Apolipoprotein M: structure and function

Bibliography

• Xu N, Dahlback B: A novel humanapolipoprotein (apoM). J. Biol. Chem.274(44), 31286–31290 (1999.
   Google Scholar
• Identification and initial characterization of apoM.
   Google Scholar
• Christoffersen C, Nielsen LB, Axler O,Andersson A, Johnsen AH, Dahlback B:Isolation and characterization of humanapolipoprotein M-containing lipoproteins.J. Lipid Res. 47(8), 1833–1843 (2006).
   Google Scholar
• ApoM-containing lipoproteins were isolated from human plasma using conventional ion exchange chromatography combined with immuno affinity chromatography using amonoclonal antibody against apoM. Theprotein and lipid contents of these lipoprotein particles were characterized.
   Google Scholar
• Axler O, Ahnstrom J, Dahlback B:Apolipoprotein M associates to lipoproteinsthrough its retained signal peptide. FEBSLett. 582(5), 826–828 (2008).
   Google Scholar
• Demonstrates that a single amino acidreplacement at position 22 results in thecreation of a signal peptidase cleavagesite. The mutant apoM is not associatedwith lipoprotein particles in contrast tonative apoM.
   Google Scholar
• Christoffersen C, Ahnstrom J, Axler O,Christensen EI, Dahlback B, Nielsen LB: Thesignal peptide anchors apolipoprotein M inplasma lipoproteins and prevents rapidclearance of apolipoprotein M from plasma.J. Biol. Chem. 283(27), 18765–1872 (2008).
   Google Scholar
• The retained signal peptide of apoM servesas an anchor for the protein to the phospholipid of the lipoprotein. This iscrucial to keep apoM in the circulation.Thus, the apoMQ22A variant, which doesnot carry a retained signal peptide and therefore does not associate withlipoproteins, is rapidly lost from the circulation owing to filtration in the kidney.
   Google Scholar
• Axler O, Ahnstrom J, Dahlback B: AnELISA for apolipoprotein M reveals a strongcorrelation to total cholesterol in humanplasma. J. Lipid Res. 48(8), 1772–1780(2007).
   Google Scholar
• First quantitative immunoassay for apoM,which in this study is used to characterize the normal variation in healthy individuals.Moreover, as many other biochemicalparameters were measured in this cohort,the correlation between apoM and the separameters in plasma could be investigated.A strong correlation between apoM andcholesterol was identified, and particularlynoteworthy was the correlation not onlywith HDL-C but also with LDL-C.
   Google Scholar
• Duan J, Dahlback B, Villoutreix BO:Proposed lipocalin fold forapolipoprotein M based on bioinformaticsand site-directed mutagenesis. FEBS Lett.499(1–2), 127–132 (2001).
   Google Scholar
• Demonstration of the lipocalin nature ofapoM and description of a molecularmodel of apoM.
   Google Scholar
• Ahnstrom J, Faber K, Axler O,Dahlback B: Hydrophobic ligand bindingproperties of the human lipocalinapolipoprotein M. J. Lipid Res. 48(8),1754–1762 (2007).
   Google Scholar
• Wolfrum C, Poy MN, Stoffel M:Apolipoprotein M is required forpre-HDL formation and cholesterol effluxto HDL and protects against atherosclerosis.Nat. Med. 11(4), 418–422 (2005).
   Google Scholar
• Christoffersen C, Jauhiainen M, Moser Met al.: Effect of apolipoprotein M on highdensity lipoprotein metabolism and atherosclerosis in low density lipoproteinreceptor knock-out mice. J. Biol. Chem.283(4), 1839–1847 (2008).
   Google Scholar
• Description of an apoM-knockout mousethat demonstrates that apoM is notabsolutely required for the formation ofpre- HDL, as had previously beenclaimed. Moreover, the plasma lipoprotein profile in plasma of the knockout mice wasessentially normal. The availability ofknockout and transgenic mice paves theway for future studies of apoM physiology.
   Google Scholar
• Ahnstrom J, Axler O, Jauhiainen M et al.:Levels of apolipoprotein M are notassociated with the risk of coronary heartdisease in two independent case–controlstudies. J. Lipid Res. DOI:10.1194/jlr.M700471-JLR200 (2008)(Epub ahead of print).
   Google Scholar
• Two case–control studies of cohorts drawnfrom the normal population and followedfor many years demonstrate that apoMconcentration in plasma does not predictcoronary heart disease.
   Google Scholar
• Karlsson H, Leanderson P, Tagesson C,Lindahl M: Lipoproteomics II: mapping ofproteins in high-density lipoprotein usingtwo-dimensional gel electrophoresis andmass spectrometry. Proteomics 5(5),1431–1445 (2005).
   Google Scholar
• Karlsson H, Leanderson P, Tagesson C,Lindahl M: Lipoproteomics I: mapping ofproteins in low-density lipoprotein usingtwo-dimensional gel electrophoresis andmass spectrometry. Proteomics 5(2),551–565 (2005).
   Google Scholar
• Flower DR: The lipocalin protein family:structure and function. Biochem. J.318(Pt 1), 1–14 (1996).
   Google Scholar
• Schlehuber S, Skerra A: Lipocalins indrug discovery: from naturalligand-binding proteins to 舖anticalins'.Drug Discov. Today 10(1), 23–33(2005).
   Google Scholar
• Choi SH, Kwak SH, Youn BS et al.: Highplasma retinol binding protein-4 and lowplasma adiponectin concentrations areassociated with severity of glucoseintolerance in women with previousgestational diabetes mellitus. J. Clin.Endocrinol. Metab. 93(8), 3142–3148(2008).
   Google Scholar
• Faber K, Hvidberg V, Moestrup SK,Dahlback B, Nielsen LB: Megalin is areceptor for apolipoprotein M, andkidney-specific megalin-deficiency confersurinary excretion of apolipoprotein M.Mol. Endocrinol. 20(1), 212–218(2006).
   Google Scholar
• Raper J, Fung R, Ghiso J, Nussenzweig V,Tomlinson S: Characterization of a noveltrypanosome lytic factor from humanserum. Infect. Immun. 67(4), 1910–1916(1999).
   Google Scholar
• Smith AB, Esko JD, Hajduk SL: Killing oftrypanosomes by the human haptoglobinrelatedprotein. Science 268(5208),284–286 (1995).
   Google Scholar
• Dalbey RE, Lively MO, Bron S,van Dijl JM: The chemistry andenzymology of the type I signalpeptidases. Protein Sci. 6(6), 1129–1138(1997).
   Google Scholar
• Faber K, Axler O, Dahlback B,Nielsen LB: Characterization of apoMin normal and genetically modified mice.J. Lipid Res. 45(7), 1272–1278(2004).
   Google Scholar
• Zhang XY, Dong X, Zheng Let al.: Specific tissue expression andcellular localization of humanapolipoprotein M as determined by in situhybridization. Acta Histochem. 105(1),67–72 (2003).
   Google Scholar
• Feingold KR, Shigenaga JK,Chui LG, Moser A, Khovidhunkit W,Grunfeld C: Infection and inflammation decrease apolipoprotein M expression.Atherosclerosis 199(1), 19–26(2007).
   Google Scholar
• Xu WW, Zhang Y, Tang YB et al.:A genetic variant of apolipoprotein Mincreases susceptibility to coronary arterydisease in a Chinese population. Clin. Exp.Pharmacol. Physiol. 35(5–6), 546–551 (2008).
   Google Scholar
• Niu N, Zhu X, Liu Y et al.: Singlenucleotide polymorphisms in the proximalpromoter region of apolipoprotein M gene(apoM) confer the susceptibility todevelopment of Type 2 diabetes in HanChinese. Diabetes Metab. Res. Rev. 23(1),21–25 (2007).
   Google Scholar
• Jiao GQ, Yuan ZX, Xue YS et al.:A prospective evaluation ofapolipoprotein M gene T-778Cpolymorphism in relation to coronaryartery disease in Han Chinese. Clin.Biochem. 40(15), 1108–1112 (2007).
   Google Scholar
• Venteclef N, Smith JC, Goodwin B,Delerive P: Liver receptor homolog 1 is anegative regulator of the hepatic acutephaseresponse. Mol. Cell. Biol. 26(18),6799–6807 (2006).
   Google Scholar
• Richter S, Shih DQ, Pearson ER et al.:Regulation of apolipoprotein M geneexpression by MODY3 gene hepatocytenuclear factor-1 : haploin sufficiency isassociated with reduced serumapolipoprotein M levels. Diabetes 52(12),2989–2995 (2003).
   Google Scholar
• Demonstration that hepatic nuclearfactor-1 is an important transcriptionfactor for apoM.
   Google Scholar
• Wolfrum C, Howell J, Ndungo E,Stoffel M: Foxa2 activity increases plasmaHDL levels by regulating apolipoproteinM. J. Biol. Chem. 283(24), 16940–16949(2008).
   Google Scholar
• Shih DQ, Bussen M, Sehayek E et al.:Hepatocyte nuclear factor-1 is an essentialregulator of bile acid and plasmacholesterol metabolism. Nat. Genet. 27(4),375–382 (2001).
   Google Scholar
• Pontoglio M: Hepatocyte nuclear factor 1,a transcription factor at the crossroads ofglucose homeostasis. J. Am. Soc. Nephrol.11 (Suppl. 16), S140–S143 (2000).
   Google Scholar
• Giuffrida FM, Reis AF: Genetic andclinical characteristics of maturity-onsetdiabetes of the young. Diabetes Obes.Metab. 7(4), 318–326 (2005).
   Google Scholar
• Nitta M, Ku S, Brown C, Okamoto AY,Shan B: CPF: an orphan nuclear receptorthat regulates liver-specific expression ofthe human cholesterol 7 -hydroxylasegene. Proc. Natl Acad. Sci. USA 96(12),6660–6665 (1999).
   Google Scholar
• del Castillo-Olivares A, Gil G: 1-fetoprotein transcription factor isrequired for the expression of sterol12 -hydroxylase, the specific enzyme forcholic acid synthesis. Potential role in thebile acid-mediated regulation of genetranscription. J. Biol. Chem. 275(23),17793–17799 (2000).
   Google Scholar
• Delerive P, Galardi CM, Bisi JE,Nicodeme E, Goodwin B: Identification of liver receptor homolog-1 as a novelregulator of apolipoprotein AI genetranscription. Mol. Endocrinol. 18(10),2378–2387 (2004).
   Google Scholar
• Luo Y, Liang CP, Tall AR: The orphannuclear receptor LRH-1 potentiates thesterol-mediated induction of thehuman CETP gene by liver X receptor.J. Biol. Chem. 276(27), 24767–24773(2001).
   Google Scholar
• Schoonjans K, Annicotte JS, Huby T et al.:Liver receptor homolog 1 controls theexpression of the scavenger receptor class Btype I. EMBO Rep. 3(12), 1181–1187(2002).
   Google Scholar
• Venteclef N, Haroniti A, Tousaint JJ,Talianidis I, Delerive P: Regulation of antiatherogenicapolipoprotein M geneexpression by the orphan nuclear receptorLRH-1. J. Biol. Chem. 283(7), 3694–3701(2008).
   Google Scholar
• Demonstrates that liver receptorhomolog-is an important regulator ofapoM expression.
   Google Scholar
• Huang J, Iqbal J, Saha PK et al.: Molecularcharacterization of the role of orphanreceptor small heterodimer partner indevelopment of fatty liver. Hepatology46(1), 147–157 (2007).
   Google Scholar
• Sund NJ, Vatamaniuk MZ, Casey M et al.:Tissue-specific deletion of Foxa2 inpancreatic cells results inhyperinsulinemic hypoglycemia. GenesDev. 15(13), 1706–1715 (2001).
   Google Scholar
• Lee CS, Friedman JR, Fulmer JT,Kaestner KH: The initiation of liverdevelopment is dependent on Foxatranscription factors. Nature 435(7044),944–947 (2005).
   Google Scholar
• Sorenson RC, Bisgaier CL, Aviram M,Hsu C, Billecke S, La Du BN: Humanserum paraoxonase/arylesterase's retainedhydrophobic N-terminal leader sequenceassociates with HDLs by bindingphospholipids: apolipoprotein A-Istabilizes activity. Arterioscler. Thromb.Vasc. Biol. 19(9), 2214–2225(1999).
   Google Scholar
• Skupien J, Kepka G, Gorczynska-Kosiorz Set al.: Evaluation of apolipoprotein Mserum concentration as a biomarker of HNF-1 MODY. Rev. Diabet. Stud. 4(4),231–235 (2007).
   Google Scholar
• Mensah GA, Brown DW, Croft JB,Greenlund KJ: Major coronary risk factorsand death from coronary heart disease:baseline and follow-up mortality data fromthe Second National Health and NutritionExamination Survey (NHANES II). Am. J.Prev. Med. 29(5 Suppl. 1), 68–74 (2005).
   Google Scholar
• Kannel WB, Castelli WP, Gordon T,McNamara PM: Serum cholesterol,lipoproteins, and the risk of coronary heartdisease. The Framingham study. Ann.Intern. Med. 74(1), 1–12 (1971).
   Google Scholar
• Kannel WB, Neaton JD, Wentworth Det al.: Overall and coronary heart diseasemortality rates in relation to major riskfactors in 325,348 men screened for the MRFIT. Multiple Risk Factor InterventionTrial. Am. Heart J. 112(4), 825–836 (1986).
   Google Scholar